Literature DB >> 30972167

Down-regulation of intracellular reactive oxygen species attenuates P-glycoprotein-associated chemoresistance in Epstein-Barr virus-positive NK/T-cell lymphoma.

Young-Sun Nam1,2,3, Keon-Il Im1,3, Nayoun Kim1,3, Yunejin Song1,2,3, Jun-Seok Lee1,2,3, Young-Woo Jeon1,3,4, Seok-Goo Cho1,2,3,4.   

Abstract

Epstein-Barr virus (EBV)-positive extranodal NK/T-cell lymphoma is a rare and highly aggressive disease with a poor prognosis and strong resistance to anti-cancer drugs. Reactive oxygen species (ROS) are closely related to tumorigenesis and P-glycoprotein (P-gp) is highly expressed in various cancers. However, the exact relationship between ROS and P-gp in EBV-positive lymphoma remains unclear. In this study, we demonstrated that EBV latent infection induced intracellular ROS production and increased ROS levels triggered elevated P-gp expression, which resulted in strong resistance to existing anti-cancer drugs in EBV-positive lymphoma cell lines and in patients' tissue samples. We also verified that regulation of intracellular ROS reduced P-gp expression and function via inhibition of STAT1 phosphorylation. These results indicate that treatment with a ROS scavenger is a potential therapeutic strategy to overcome resistance to anti-cancer drugs by downregulating the expression of P-gp in EBV-positive NK/T-cell lymphoma.

Entities:  

Keywords:  Epstein-Barr virus (EBV); P-glycoprotein (P-gp); extranodal NK/T-cell lymphoma (ENKTCL); multi-drug resistance (MDR); reactive oxygen species (ROS)

Year:  2019        PMID: 30972167      PMCID: PMC6456522     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  7 in total

1.  Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.

Authors:  Yuchen Zhang; Shuyun Ma; Jun Cai; Yu Yang; Hongmei Jing; Yuerong Shuang; Zhigang Peng; Bingzong Li; Panpan Liu; Zhongjun Xia; Yi Xia; Yan Gao; Daoguang Chen; Jianyang Lin; Qihui Li; Shenghua Xu; Qingyuan Xu; Han Zhang; Huiqiang Huang; Qingqing Cai
Journal:  Am J Hematol       Date:  2021-09-13       Impact factor: 13.265

2.  Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.

Authors:  Hua Wang; Liang Wang; Chun Li; Zhijun Wuxiao; Guanjun Chen; Wei Luo; Yue Lu
Journal:  Oncologist       Date:  2020-07-29

3.  Impact of Epstein-Barr Virus on Peripheral T-Cell Lymphoma Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma.

Authors:  Tong-Yoon Kim; Gi-June Min; Young-Woo Jeon; Sung-Soo Park; Silvia Park; Seung-Hawn Shin; Seung-Ah Yahng; Jae-Ho Yoon; Sung-Eun Lee; Byung-Sik Cho; Ki-Seong Eom; Yoo-Jin Kim; Seok Lee; Hee-Je Kim; Chang-Ki Min; Jong-Wook Lee; Seok-Goo Cho
Journal:  Front Oncol       Date:  2022-01-11       Impact factor: 6.244

4.  The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining.

Authors:  Dong Xu; Yiqi Zhang; Feng Jin
Journal:  BMC Cancer       Date:  2021-12-09       Impact factor: 4.430

Review 5.  Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas.

Authors:  Jungang Chen; Samantha Kendrick; Zhiqiang Qin
Journal:  Viruses       Date:  2019-12-16       Impact factor: 5.048

6.  HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial function and EBV suppression.

Authors:  Qi Chen; Jia Feng; Jinhu Wu; Zhendong Yu; Wei Zhang; Yonggang Chen; Paul Yao; Hongyu Zhang
Journal:  Leukemia       Date:  2020-03-23       Impact factor: 11.528

7.  Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1β Signaling Pathway.

Authors:  Jia Feng; Qi Chen; Ping Zhang; Xiaodong Huang; Weiguo Xie; Hongyu Zhang; Paul Yao
Journal:  Stem Cell Rev Rep       Date:  2021-01-09       Impact factor: 5.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.